Ocrelizumab in Multiple Sclerosis: Risks and Benefits – Author's ReplyLudwig Kappos,David Leppert, Jeroen Timmermann,Robert Glanzman,Stephen L. HauserLancet(2012)引用 3|浏览2暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要